InvestorsHub Logo
Followers 22
Posts 747
Boards Moderated 0
Alias Born 09/07/2016

Re: jessellivermore post# 205615

Saturday, 08/03/2019 4:52:45 PM

Saturday, August 03, 2019 4:52:45 PM

Post# of 425923
JL - I appreciate the line of thinking that a post label change secondary offering would be at a higher price but I think it was smarter to do it prior.
It was done at an all time high in the market and no one can predict market conditions in 2-3 months. We could of been trading at below 18.
We have some momentum with rising rx’s, ADA,ICER, likely AHA/ACC. Makes sense to me to hit the ground running with DTC, CME ramp up and increased reps when the decision comes out.
Insurance coverage is key We need to overwhelm the insurers to change tiers before 2020 and that means hiring folks now and not in October
If they are seriously considering a BO and BP wants to see the label change first then they are in a stronger negotiating position
Although highly unlikely IMO, if there was an FDA hiccup we protect ourselves with the raise
No one is happy with the 25% haircut but I think it was a smart mid- long term decision- We’ll see who is right in 6 months or so :)
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News